Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Stock Moves -1.74%: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.25, moving -1.74% from the previous trading session.

Zacks Equity Research

Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.

Zacks Equity Research

Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA

by Zacks Equity Research

With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.54, moving +0.45% from the previous trading session.

Zacks Equity Research

Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Rimmi Singhi headshot

5 Best High Earnings Yield Picks to Grow Your Wealth

by Rimmi Singhi

Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed at $15.87 in the latest trading session, marking a -1.43% move from the prior day.

Zacks Equity Research

Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.